7876 related articles for article (PubMed ID: 2462749)
41. [Second cancers in hematologic malignancies (epidemiologic observations from a 20-year period)].
Jakó J; Szerafin L; Nagy P
Orv Hetil; 2005 Mar; 146(10):461-9. PubMed ID: 15835344
[TBL] [Abstract][Full Text] [Related]
42. The role of interferons in the treatment of malignant neoplasms.
Murren JR; Buzaid AC
Yale J Biol Med; 1989; 62(3):271-90. PubMed ID: 2479178
[TBL] [Abstract][Full Text] [Related]
43. Biological molecules in the treatment of hematological disorders.
Kurzrock R; Talpaz M; Gutterman U
Sangre (Barc); 1989 Feb; 34(1):53-8. PubMed ID: 2469130
[No Abstract] [Full Text] [Related]
44. [Interferons in the treatment of hematological diseases].
Jantunen E; Nousiainen T
Duodecim; 1998; 114(12):1240-7. PubMed ID: 11524770
[No Abstract] [Full Text] [Related]
45. The role of interferon in the therapy of malignant lymphoma.
McLaughlin P
Biomed Pharmacother; 1996; 50(3-4):140-8. PubMed ID: 8881370
[TBL] [Abstract][Full Text] [Related]
46. [Gamma interferon therapy of cancer patients].
Kobayashi Y; Urabe A
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):804-9. PubMed ID: 3133983
[TBL] [Abstract][Full Text] [Related]
47. [Interferons, a class of cytokines with a large therapeutic activity range].
Billard C
Bull Cancer; 1993 Sep; 80(9):741-56. PubMed ID: 7515733
[TBL] [Abstract][Full Text] [Related]
48. [Antineoplastic effects of interferons].
Shimoyama M
Nihon Rinsho; 1986 Feb; 44(2):395-402. PubMed ID: 2422409
[No Abstract] [Full Text] [Related]
49. Interferons in the treatment of human cancer.
Kirkwood JM; Ernstoff MS
J Clin Oncol; 1984 Apr; 2(4):336-52. PubMed ID: 6323641
[TBL] [Abstract][Full Text] [Related]
50. Biannual report of the Cochrane Haematological Malignancies Group.
Trelle S; Higgins G; Kober T; Engert A
J Natl Cancer Inst; 2004 Aug; 96(15):E2. PubMed ID: 15292394
[No Abstract] [Full Text] [Related]
51. Cytotoxic effect of interferon on primary malignant tumour cells. Studies in various malignancies.
Grandér D; Xu B; Einhorn S
Eur J Cancer; 1993; 29A(14):1940-3. PubMed ID: 7506559
[TBL] [Abstract][Full Text] [Related]
52. Leukemias and myeloma.
Wiernik PH
Cancer Chemother Biol Response Modif; 1988; 10():129-47. PubMed ID: 3079381
[No Abstract] [Full Text] [Related]
53. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
54. [Clinical use of interferon].
Lauta VM
Clin Ter; 1996; 147(7-8):345-51. PubMed ID: 9118615
[TBL] [Abstract][Full Text] [Related]
55. [Immunocytologic diagnosis of leukemia and lymphoma: monoclonal antibodies in the differential diagnosis of hematologic neoplasms].
Huber H; Gattringer C; Thaler J; Peschel C
Behring Inst Mitt; 1985 Dec; (78):83-117. PubMed ID: 3914283
[TBL] [Abstract][Full Text] [Related]
56. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
57. Interferons. New additions and indications for use.
Stadler R; Ruszczak Z
Dermatol Clin; 1993 Jan; 11(1):187-99. PubMed ID: 7679614
[TBL] [Abstract][Full Text] [Related]
58. Clinical use of biologic response modifiers in cancer treatment: an overview. Part I. The interferons.
Balmer CM
DICP; 1990; 24(7-8):761-8. PubMed ID: 1695795
[TBL] [Abstract][Full Text] [Related]
59. Biotherapy with interferon in solid tumors.
Figlin RA
Oncol Nurs Forum; 1987; 14(6 Suppl):23-31. PubMed ID: 2447570
[No Abstract] [Full Text] [Related]
60. [Interferons, interleukin-2 and tumor necrosis factor. New approaches to cancer therapy].
Oettgen HF
Arzneimittelforschung; 1987 Feb; 37(2A):251-5. PubMed ID: 2436634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
